IDH1 and acute myeloid leukemia: A phase Ib trial tested the combination of ivosidenib plus azacitidine in 23 newly diagnosed IDH1-mutated AML patients ineligible for intensive chemotherapy, showing an ORR and CR rate of 78.3% and 60.9%, respectively, and a 12-month survival of 82% [170].